Artificial intelligence (AI) is ubiquitous, and it was only a matter of time before this technology was adopted by the medical device industry. The Covid-19 pandemic has been one of the catalysts for this adoption, as many businesses and hospitals felt its impact and it became necessary to adopt a new strategy to improve the diagnosis and treatment of patients.

Two companies that have recently invested in AI and machine learning (ML) are Medtronic and Philips. Medtronic acquired Medicrea, a spinal surgery company that has an AI database containing over 6,000 surgical cases. This was an enormous boost to Medtronic’s portfolio as it emphasises AI-driven surgical planning, spinal implants and robotic-assisted surgery. In December, Philips agreed to acquire BioTelemetry, a medical technology company that specialises in cardiac monitoring services. BioTelemetry’s products include wearable heart monitors and AI-based data analytics. This deal will allow Philips to tap into the market growth by expanding its remote monitoring business beyond hospitals and into patients’ homes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While AI may come across as overhyped, the potential use cases for this technology are boundless. Major medical device companies are investing millions of dollars in the technology and will continue to reap the rewards. The global market value for the technology is projected to grow to $52bn in 2024.